Revelation Biosciences, Inc. is advancing its Gemini program and plans to engage with the FDA later this year.
7 reports, 2 independent
Updated Jul 21
Gone quiet
- Reports
- 7
- Developments
- 2
- Repetition
- 86%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Revelation Biosciences, Inc. is advancing its Gemini program and plans to engage with the FDA later this year.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Gemini, a product candidate from Revelation Biosciences, is undergoing a Phase 1b clinical trial for Chronic Kidney Disease (CKD).Sub-event
Revelation Biosciences is advancing the Gemini program and planning future FDA engagement.1 source
Keep exploring
The entities involved
Related events
Coverage
Newest first; wire copies grouped- californiatelegraph.com
- Business WireRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025 SAN DIEGO, August 08, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the
- Unknown outlet